Abstract
Background: Atopic eczema (atopic dermatitis, AD) is characterized by disrupted skin barrier associated with elevated skin pH and skin microbiome dysbiosis, due to high Staphylococcus aureus loads, especially during flares. Since S aureus shows optimal growth at neutral pH, we investigated the longitudinal interplay between these factors and AD severity in a pilot study. Method: Emollient (with either basic pH 8.5 or pH 5.5) was applied double-blinded twice daily to 6 AD patients and 6 healthy (HE) controls for 8 weeks. Weekly, skin swabs for microbiome analysis (deep sequencing) were taken, AD severity was assessed, and skin physiology (pH, hydration, transepidermal water loss) was measured. Results: Physiological, microbiome, and clinical results were not robustly related to the pH of applied emollient. In contrast to longitudinally stable microbiome in HE, S aureus frequency significantly increased in AD over 8 weeks. High S aureus abundance was associated with skin pH 5.7-6.2. High baseline S aureus frequency predicted both increase in S aureus and in AD severity (EASI and local SCORAD) after 8 weeks. Conclusion: Skin pH is tightly regulated by intrinsic factors and limits the abundance of S aureus. High baseline S aureus abundance in turn predicts an increase in AD severity over the study period. This underlines the importance and potential of sustained intervention regarding the skin pH and urges for larger studies linking skin pH and skin S aureus abundance to understand driving factors of disease progression.
Original language | English |
---|---|
Pages (from-to) | 2888-2898 |
Number of pages | 11 |
Journal | Allergy: European Journal of Allergy and Clinical Immunology |
Volume | 75 |
Issue number | 11 |
DOIs | |
State | Published - 1 Nov 2020 |
Externally published | Yes |
Bibliographical note
Publisher Copyright:© 2020 The Authors. Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.
Funding
CH, KT, GH, ADT, MB, TN, AUN, MR, and CTH work at IEM, which received grants from Sebapharma GmbH & Co. KG. In addition, AUN, MR, and CTH reported the following. AUN reported grants and personal fees from Asana Biosciences, and grants from Sebapharma GmbH & Co. KG, outside the submitted work. MR received personal fees from Bencard, Germany, Roche‐Posay, Germany, Galderma, Germany, and Sebapharma, Germany, and grants from CLR, Germany, outside the submitted work. CTH reported personal fees from Novartis, Germany, Sanofi, Germany, Lilly Pharma, Germany Töpfer GmbH, Bencard, Germany, Danone Nutricia, Lancome, Germany, and Loreal, Germany, outside the submitted work.
Funders | Funder number |
---|---|
Sebapharma GmbH & Co |
Keywords
- Staphylococcus aureus
- atopic dermatitis
- microbiome
- pH
- skin